''After a median follow-up of 24.5 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly (p\0.0001) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31-0.53)''.
''After a median follow-up of 24.5 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly (p\0.0001) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31-0.53)''.
should read:
''After a median follow-up of 25.4 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly (p\0.0001) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31-0.53)''.
The original article can be found online at https://doi.org/10.1007/ s40265-017-0837-7.
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